Lercanidipine Medreg

Lercanidipine, the active ingredient in Lercanidipine Medreg, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Lercanidipine Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of high blood pressure. - Hypertension: lowers elevated systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually resolves without intervention. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing quickly. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid excessive lowering. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: start at the lowest effective dose due to increased sensitivity. - Concomitant antihypertensives: monitor for additive hypotensive effects. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels. - Other potent antihypertensives: risk of additive hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance electrolyte disturbances. - NSAIDs: can attenuate antihypertensive response.